Show simple item record

dc.contributor.authorMeiers, Isabelle
dc.contributor.authorShanks, Jonathan H
dc.contributor.authorBostwick, David G
dc.date.accessioned2009-06-11T10:59:04Z
dc.date.available2009-06-11T10:59:04Z
dc.date.issued2007-06
dc.identifier.citationGlutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. 2007, 39 (3):299-304 Pathologyen
dc.identifier.issn0031-3025
dc.identifier.pmid17558856
dc.identifier.doi10.1080/00313020701329906
dc.identifier.urihttp://hdl.handle.net/10541/70155
dc.description.abstractProstatic carcinoma is characterised by the silencing of the pi-class glutathione S-transferase gene (GSTP1), which encodes a detoxifying enzyme. The silencing of GSTP1 results from aberrant methylation at the CpG island in the promoter-5' and occurs in the vast majority of cases of high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancers. We review the potential novel role of GSTP1 and its related expression in prostate cancer. The loss of expression (silencing) of the GSTP1 gene is the most common (>90%) genetic alteration reported to date in prostate cancer. Quantitative methylation-specific PCR assays allow detection of GSTP1 methylation in prostate biopsies and may improve the sensitivity of cancer detection. Advances in the epigenetic characterisation of prostate cancer have enabled the development of DNA methylation assays that may soon be used in diagnostic testing of serum and tissue for prostate cancer. Inhibition of aberrant promoter methylation could theoretically prevent carcinogenesis.
dc.language.isoenen
dc.subjectProstate Canceren
dc.subject.meshDNA Methylation
dc.subject.meshEpigenesis, Genetic
dc.subject.meshGlutathione Transferase
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.titleGlutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, Bostwick Laboratories, London, United Kingdom. isabellemeiers@hotmail.comen
dc.identifier.journalPathologyen
html.description.abstractProstatic carcinoma is characterised by the silencing of the pi-class glutathione S-transferase gene (GSTP1), which encodes a detoxifying enzyme. The silencing of GSTP1 results from aberrant methylation at the CpG island in the promoter-5' and occurs in the vast majority of cases of high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancers. We review the potential novel role of GSTP1 and its related expression in prostate cancer. The loss of expression (silencing) of the GSTP1 gene is the most common (>90%) genetic alteration reported to date in prostate cancer. Quantitative methylation-specific PCR assays allow detection of GSTP1 methylation in prostate biopsies and may improve the sensitivity of cancer detection. Advances in the epigenetic characterisation of prostate cancer have enabled the development of DNA methylation assays that may soon be used in diagnostic testing of serum and tissue for prostate cancer. Inhibition of aberrant promoter methylation could theoretically prevent carcinogenesis.


This item appears in the following Collection(s)

Show simple item record